Meeting NewsVideo

VIDEO: Luxturna shows long-term vision improvement

VANCOUVER — At the Association for Research in Vision and Ophthalmology meeting, Bart Leroy, MD, PhD, discusses retrospective reviewsevaluating patients treated with Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics). The studies, completed by both Spark Therapeutix and Novartis, found a consistent improvement in visual function lasting up to at least 4 years.

 

Disclosure: Leroy reports no relevant financial disclosures.

VANCOUVER — At the Association for Research in Vision and Ophthalmology meeting, Bart Leroy, MD, PhD, discusses retrospective reviewsevaluating patients treated with Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics). The studies, completed by both Spark Therapeutix and Novartis, found a consistent improvement in visual function lasting up to at least 4 years.

 

Disclosure: Leroy reports no relevant financial disclosures.

    See more from Association for Research in Vision and Ophthalmology